Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tariquidar: Phase III

QLT discontinued the two Phase III trials of tariquidar in combination with first-line chemotherapy for NSCLC following a recommendation by an independent data safety and

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE